January 30, 2013 – For the first time in Canada, patients attending a family practice clinic will be offered genetic testing to see whether or how they will respond to psychiatric medication treatment, in partnership with the Centre for Addiction and Mental Health (CAMH).
Thornhill Medical Centre, a clinic of family physicians, is making the promise of personalized medicine a reality.
“These pharmacogenetic tests will enable physicians to use a patient’s genetic makeup to help predict which medications are safe to prescribe, and which ones may be ineffective or cause side effects,” said Dr. James Kennedy, head of CAMH’s Neuroscience Research Department.
The tests, which will prevent trial-and-error
prescribing and reduce associated health-care costs, will be analyzed in
the Tanenbaum Centre for Pharmacogenetics at CAMH’s Campbell Family
Mental Health Research Institute.
“My patients were ready for these tests yesterday –
they may have tried three or four different antidepressants that didn’t
work or had side effects, before finding something that helped them,”
Dr. Nick Voudouris, a family physician with the Thornhill Medical
Centre. “The ability to be able to know which medications patients will
respond to, based on their genetic predisposition, is invaluable.”
Using a saliva sample, variations on five genes are analyzed to predict a patient’s response to 19 common antidepressant and antipsychotic medications. Medications that will work get a green light to prescribe as directed. A yellow light signals caution. For each medication in this category, the tests will show whether dosing levels need to be lowered or increased, or that the drug’s effects may not be optimal for this patient. Medications in the red light category should be used with caution and more frequent monitoring, due to side effects or lack of response.
This initiative is part of the larger IMPACT study (Individualized Medicine: Pharmacogenetic Assessment & Clinical Treatment). Funded in part by the Ontario Ministry of Economic Development and Innovation, IMPACT researchers aim to look at the impact of genetic testing over seven years in 20,000 patients. They are also seeking to identify new genetic markers.
“We expect these tests to improve patient satisfaction and safety, and have a substantial impact on reducing health-care costs, which we will be examining over the course of the IMPACT study,” said Dr. Kennedy. “With the genetic information doctors will be better equipped to prevent complications from medications before they occur.”
Media contact: Michael Torres; (416) 595-6015; email@example.com. For information on test availability, please email firstname.lastname@example.org.
The Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health and addiction teaching hospital, as well as one of the world's leading research centres in its field.
CAMH combines clinical care, research, education, policy development and health promotion to help transform the lives of people affected by mental health and addiction issues. CAMH is fully affiliated with the University of Toronto, and is a Pan American Health Organization/World Health Organization Collaborating Centre. For more information, please visit www.camh.ca.